News | March 19, 2025
Croda opens advanced lipids manufacturing facility in Pennsylvania
This facility represents a significant step in Croda’s Pharma business strategy to ‘Empower biologics delivery’
This facility represents a significant step in Croda’s Pharma business strategy to ‘Empower biologics delivery’
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
Construction will begin this year with the new capacity anticipated by 2025
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
Agilent respectfully disagrees with the PTAB’s opinion of unpatentability in view of prior art previously considered by the USPTO during its primary examination
OmiCrisp has been developed with support from Centre for Cellular And Molecular Platforms C-CAMP-InDx Program
This partnership expands DNA Script’s footprint and provides sales and support for the SYNTAX System DNA printer in labs in India
Shoreline has developed a proprietary methodology to create differentiated iNK cells for large-scale, "off-the-shelf" production
Subscribe To Our Newsletter & Stay Updated
